Ibex Medical Analytics Announces Expansion of its Biopharma Business, Extending AI Pathology Platform into Early Biomarker Development

Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced a significant expansion of ...

Immunotherapy and AI Biomarker Advances Might Change The Case For Investing In Roche Holding (SWX:ROG)

In recent developments, Roche has featured prominently in the race to develop TIGIT inhibitors for cancer immunotherapy, ...
Kauppalehti

Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
The Scientist

Improving Protein Biomarker Development

Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...
Multiple Sclerosis News Today

New biomarker may help identify MS patients for BTK inhibitors

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

Genomic Biomarkers Market worth $50.31 billion by 2030 | MarketsandMarkets™

According to MarketsandMarkets™, the Genomic Biomarkers Market is projected to grow from about USD 29.00 billion in 2025 to ...
Yahoo Finance

Global Cancer Biomarkers Market Size to Reach USD 72.64 Billion by 2032, Driven by Precision Oncology and Early Detection Advancements - SNS Insider

Austin, July 21, 2025 (GLOBE NEWSWIRE) -- Cancer Biomarkers Market Size & Growth Analysis: According to SNS Insider, the global Cancer Biomarkers Market was valued at USD 31.09 billion in 2024 and is ...
Pharm Exec

Navigating the Increasing Complexity of Drug-Biomarker Co-Development

To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative ...
FierceBiotech

How Biomarker Signatures can help de-risk drug development

We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...